Ulysses Ribeiro |
|
M.D., PhD
|
| a |
| a |
| a |
| a |
34.02
Skills (4)
-
18 Questions167 Followers
-
27 Questions5252 Followers
-
13 Questions5268 Followers
-
25 Questions6747 Followers
Other
-
LanguagesPortuguese
English -
Scientific MembershipsBrazilian College of Digestive Surgery
Brazilian College of Surgeons
Brazilian Society of Colo-proctology
Associação Paulista de Medicina
Society of Alimentary Tract - USA
American College of Gastroenterology
Society of Surgical Oncology - USA
International College of Surgeons
International Society for Diseases of the Esophagus -
Journal RefereesArquivos de Gastroenterologia, Esophagus, Journal of surgical oncology. Supplement, Annals of Surgical Oncology, Clinics
Publications (75) View all
-
Article: Endoscopic removal of migrated esophageal stent--the "grasper and pusher" method.
B Martins, M P Sorbello, F Retes, F S Kawaguti, M S Lima, F Y Hondo, G Stelko, U Ribeiro, F Maluf-FilhoEndoscopy 04/2012; 44 Suppl 2 UCTN:E10. · 5.21 Impact Factor -
Article: Transduodenal endosonography-guided biliary drainage and duodenal stenting for palliation of malignant obstructive jaundice and duodenal obstruction.
Fauze Maluf-Filho, Felipe Alves Retes, Carla Zanellato Neves, Cezar Fabiano Manabu Sato, Fabio Shiguehissa Kawaguti, Ricardo Jureidini, Ulysses Ribeiro, Telesforo Bacchella[show abstract] [hide abstract]
ABSTRACT: Endosonography-guided biliary drainage has been used over the last few years as a salvage procedure when endoscopic retrograde cholangiopancreatography fails. Malignant gastric outlet obstruction may also be present in these patients. We report the results of both procedures during the same session in patients with duodenal and biliary obstruction due to malignant disease. A retrospective review from a prospective collected database. Technical success was achieved in all five patients; however, only three patients experienced relief of jaundice and gastric outlet obstruction. Endosonography-guided biliary drainage and duodenal stenting in the same session is feasible. However, severe complications may limit the procedure. This is a challenging procedure and should be done by experts with special attention to patient's selection.JOP: Journal of the pancreas 01/2012; 13(2):210-4. -
SourceAvailable from: Ulysses Ribeiro
Article: Squamous cell carcinoma and neuroendocrine carcinoma colliding in the esophagus.
André Roncon Dias, Rubens Antonio Aissar Sallum, Nathalia Zalc, Bruno Brito Ctenas, Ulysses Ribeiro, Ivan CecconelloClinics (São Paulo, Brazil) 01/2010; 65(1):114-7. · 1.59 Impact Factor -
Article: Adenocarcinoma of the esophagogastric junction: relationship between clinicopathological data and p53, cyclin D1 and Bcl-2 immunoexpressions.
Dárcio Matenhauer Lehrbach, Ivan Cecconello, Ulysses Ribeiro Jr, Vera Luiza Capelozzi, Alexandre Muxfeldt Ab'saber, Venâncio Avancini Ferreira Alves[show abstract] [hide abstract]
ABSTRACT: Esophagogastric junction adenocarcinoma has an aggressive behavior, and TNM (UICC) staging is not always accurate enough to categorize patient's outcome. To evaluated p53, cyclin D1 and Bcl-2 immunoexpressions in esophagogastric junction adenocarcinoma patients, without Barrett's esophagus, and to compared to clinicopathological characteristics and survival rate. Tissue sections from 75 esophagogastric junction adenocarcinomas resected from 1991 to 2003 were analyzed by immunohistochemistry for p53, cyclin D1 and Bcl-2 using streptavidin-biotin-peroxidase method. The mean follow-up time was 60 months SD = 61.5 (varying from 4 to 273 months). Fifty (66.7%) of the tumors were intestinal type and 25 (33.3%) were diffuse. Vascular, lymph node and perineural infiltration were verified in 16%, 80% and 68% of the patients, respectively. The patients were distributed according to the TNM staging in IA in 4 (5.3%), IB in 10 (13.3%), II in 15 (20%), IIA in 15 (20%), IIIB in 15 (20%) and IV in 16 (21.3%). Immunohistochemical analysis was positive for p53, cyclin D1 and bcl-2 in 68%, 18.7% and 100%, respectively. There was no association between immunoexpression and vascular and/or perineural invasions, clinicopathological characteristics and patients' survival rate. In this selected population, there was no association between the immunomarkers, p53, cyclin D1 and bcl-2 and clinicopathological data and/or overall survival.Arquivos de gastroenterologia 12/2009; 46(4):315-20. -
Article: Preoperative Gastric Acid Secretion and the Risk to Develop Barrett’s Esophagus After Esophagectomy for Chagasic Achalasia
Julio Rafael Mariano da Rocha, Ivan Cecconello, Ulysses Ribeiro, Elisa R. Baba, Adriana Vaz Safatle-Ribeiro, Kiyoshi Iriya, Rubens A. A. Sallum, Paulo Sakai, Sérgio Szachnowicz[show abstract] [hide abstract]
ABSTRACT: IntroductionThe aim of this study was to determine the contribution of preoperative gastric secretory and hormonal response, to the appearance of Barrett’s esophagus in the esophageal stump following subtotal esophagectomy. MethodsThirty-eight end-stage chagasic achalasia patients submitted to esophagectomy and cervical gastric pull-up were followed prospectively for a mean of 13.6 ± 9.2years. Gastric acid secretion, pepsinogen, and gastrin were measured preoperatively in 14 patients who have developed Barrett’s esophagus (Group I), and the results were compared to 24 patients who did not develop Barrett’s esophagus (Group II). ResultsIn the group (I), the mean basal and stimulated preoperative gastric acid secretion was significantly higher than in the group II (basal: 1.52 vs. 1.01, p = 0.04; stimulated: 20.83 vs. 12.60, p = 0.01). Basal and stimulated preoperative pepsinogen were also increased at the Group I compared to Group II (Basal = 139.3 vs. 101.7, p = 0.02; stimulated = 186.0 vs. 156.5, p = 0.07. There was no difference in preoperative gastrin between the two groups. Gastritis was present during endoscopy in 57.1% of the Group I, while it was detected in 16.6% of the Group II, p = 0.014. ConclusionsBarrett’s esophagus in the esophageal stump was associated to high preoperative levels of gastric acid secretion, serum pepsinogen, and also gastritis in the transposed stomach.Journal of Gastrointestinal Surgery 11/2009; 13(11):1893-1899. · 2.83 Impact Factor